Anagram Therapeutics

About Anagram Therapeutics

Anagram Therapeutics is a biopharmaceutical company dedicated to developing breakthrough orally-delivered enzyme therapies for rare, life-threatening diseases, specifically targeting Malabsorption Syndromes and Nutrient Metabolism Disorders. Inspired by the patients they aim to help, their mission is to realign expectations, reimagine treatments, and rethink possibilities to improve the lives of infants, children, adults, and their families affected by these conditions.

Products & Services

ANG003:A new class of enzyme replacement therapy for exocrine pancreatic insufficiency and malabsorption syndromes, offering broad-spectrum composition (lipase for fat, protease for protein, amylase for carbohydrate) to make a life-changing impact for those requiring oral ERT. Currently in Phase 3.

ANG011:Engineered for Congenital Malabsorptive Syndrome to break down specific carbohydrates due to enzyme deficiencies, aiming to avoid severe complications associated with carbohydrate malabsorption. Currently in preclinical stage.

ANG003

Specialties

Orally-delivered enzyme therapeutics Malabsorption Syndromes Nutrient Metabolism Disorders Enzyme replacement therapy Gastrointestinal physiology orally delivered enzyme therapeutics rare diseases cystic fibrosis exocrine pancreatic insufficiency enzyme replacement therapy

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Strategic Investment T: - FT: Strategic Investment	A: 250000000 MR: - FA: $250 million FAN: 250000000	D: 2026-05-07 FD: 2026-05-07	1 investors
2	RT: Grant/Non-equity Funding T: - FT: Grant/Non-equity Funding	A: 15500000 MR: - FA: $15.5 million FAN: 15500000	D: 2023-04-04 FD: 2023-04-04	1 investors

Strategic Investment Latest

2026-05-07

$250.0M

1 investor (Pro only)

Grant/Non-equity Funding 2023-04-04

$15.5M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Robert Gallotto

President and Chief Executive Officer

E

Evan Bailey

Chief Medical Officer

D

David Brown

Chief of Technology Development

T

Tim Caffrey

Vice President of Finance

M

Marcie Clarkin

Vice President of Clinical Strategic Operations

J

Julie Constable

Executive Vice President, General Counsel & Head of Corporate Development

View 14 more team members with Pro

Unlock Full Team Directory

Recent News